Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

NCT01967576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Pheochromocytoma
Paraganglioma

Interventions

DRUG: Axitinib (AG-013736)

Sponsor

National Cancer Institute (NCI)